Breaking news this morning is that the GlaxoSmithKline diabetes drug Avandia will stay on the US market . Avandia, which has faced major controversy over the last few months due to its association with an increased risk of heart attack, could have faced a blanket market ban.
Two of the principal advisory committees behind the Food and Drug Administration (FDA) voted to keep Avandia on the market. This is despite an increased evidence of heart attack amongst diabetic patients taking the drug. The voting stood 22 to 1, and the FDA are expected to follow the decision.
Glaxo made £1.4 billion in sales of the drug throughout the entire world last year, and will no doubt be celebrating the decision. Avandia is designed to make the body more sensitive to insulin. The thumbs up for Avandia came despite almost universal agreement that Avandia does show a ‘suggested’ risk of heart disease and death. Whether physicians will continue to prescribe the drug, and diabetics take it, remains to be seen.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…